Research analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.
Oragenics Price Performance
Shares of NYSE:OGEN opened at $1.12 on Friday. Oragenics has a 52-week low of $0.97 and a 52-week high of $7.74. The firm has a market cap of $5.00 million, a P/E ratio of -0.13 and a beta of 0.50. The firm has a 50-day moving average price of $1.61.
Oragenics (NYSE:OGEN – Get Free Report) last issued its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Oragenics
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Recommended Stories
- Five stocks we like better than Oragenics
- What is the Hang Seng index?
- Top 3 Defense Stocks That Should Be on Your Radar
- 3 Monster Growth Stocks to Buy Now
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.